Gelonghui June 7th 丨Kehua Biotech (002022.SZ) was surveyed by the agency. During the Q&A session, “Has the company laid out the pet market?”
The company replied that the rapid development of the Chinese pet market has led to a rise in demand for pet diagnosis and treatment. The company is developing biochemicals, coagulation, luminescent POCT and other products, and achieving a zero breakthrough in the pet market is one of the company's 2023 business plans.